Smart Tools, Safer Patients: Dr. Arpita Hazra Talks AI in Healthcare

In this insightful episode of the ConCensis podcast, host Amy Chodroff welcomes Dr. Arpita Hazra, a Clinical Patient Safety Data Specialist, to explore the evolving landscape of patient safety, risk management, and AI in healthcare. Drawing from her background in internal medicine, public health, and clinical data science, Dr. Hazra provides a compelling look at how hospitals and surgical centers can minimize risk—particularly through better sterilization, communication, and the integration of AI technologies.

The conversation highlights real-world challenges, such as retained surgical instruments and post-op infections, and introduces the power of tools like CensisAI² in helping to automate instrument counts, improve documentation, and drive better patient outcomes. Dr. Hazra also emphasizes the importance of transparency and stakeholder involvement in the adoption of new technologies in the clinical environment.

Key Takeaways:

  • Sterile processing errors can lead to increased hospital stays, readmissions, and legal risks—emphasizing the need for precise, accountable systems.
  • RFID and AI-driven tools are improving documentation and surgical instrument tracking, helping reduce retained foreign objects and post-op complications.
  • CensisAI² supports hospitals with sterilization, inspection, and backend data reporting, enabling predictive analytics and better decision-making.
  • Technology adoption succeeds when frontline staff are involved early, and communication around purpose and data usage is transparent and consistent.

As healthcare systems continue to modernize, Dr. Hazra’s insights underscore the critical role of combining human vigilance with advanced tools to improve outcomes. By embracing innovation thoughtfully and fostering open dialogue across teams, hospitals can reduce risk, build trust, and ultimately deliver safer, more reliable care.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…